Tomas Kalincik
Overview
Explore the profile of Tomas Kalincik including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
208
Citations
2748
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dzau W, Roos I, Kalincik T
J Neurol Neurosurg Psychiatry
. 2025 Mar;
PMID: 40050011
Background: The ASCEND trial did not find benefit of natalizumab during secondary progressive multiple sclerosis compared with placebo; however, its open-label extension suggests this may be obscured by therapeutic lag.We...
2.
Foong Y, Merlo D, Gresle M, Zhu C, Buzzard K, Lechner-Scott J, et al.
Ann Clin Transl Neurol
. 2025 Feb;
PMID: 40007145
Background: Cognitive impairment is one of the most common and debilitating symptoms of relapsing-remitting multiple sclerosis (RRMS). Digital cognitive biomarkers require less time and resources and are rapidly gaining popularity...
3.
Toscano S, Spelman T, Ozakbas S, Alroughani R, Chisari C, Lo Fermo S, et al.
Neurotherapeutics
. 2025 Feb;
22(2):e00552.
PMID: 39965993
Predicting long-term prognosis and choosing the appropriate therapeutic approach in patients with Multiple Sclerosis (MS) at the time of diagnosis is crucial in view of a personalized medicine. We investigated...
4.
Dhondt R, Dedja K, Aerts S, Van Wijmeersch B, Kalincik T, Reddel S, et al.
Comput Methods Programs Biomed
. 2025 Feb;
263:108624.
PMID: 39965473
Background: Prognostic machine learning research in multiple sclerosis has been mainly focusing on black-box models predicting whether a patients' disability will progress in a fixed number of years. However, as...
5.
Muller J, Sharmin S, Lorscheider J, Horakova D, Kubala Havrdova E, Eichau S, et al.
CNS Drugs
. 2025 Feb;
39(4):403-416.
PMID: 39953338
Background: In relapsing-remitting multiple sclerosis (RRMS), extended exposure to high-efficacy disease modifying therapy may increase the risk of side effects, compromise treatment adherence, and inflate medical costs. Treatment de-escalation, here...
6.
Shipley J, Beharry J, Yeh W, Seery N, Foong Y, Ayton D, et al.
Med J Aust
. 2025 Feb;
PMID: 39923190
Introduction: Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disease of the central nervous system with rapidly evolving treatment options and strategies. An iterative modified Delphi process was used...
7.
Shipley J, Beharry J, Yeh W, Seery N, Foong Y, Ayton D, et al.
Med J Aust
. 2025 Feb;
PMID: 39923189
Introduction: Multiple sclerosis (MS) is a chronic inflammatory demyelinating and degenerative disease of the central nervous system. There were 33 335 people with MS in Australia in 2021 and 2917...
8.
Foong Y, Merlo D, Gresle M, Zhu C, Buzzard K, Lechner-Scott J, et al.
Eur J Neurol
. 2024 Dec;
32(1):e70000.
PMID: 39714314
Background: Upper limb dysfunction is a common debilitating feature of relapsing-remitting multiple sclerosis (RRMS). We aimed to examine the longitudinal trajectory of the iPad®-based Manual Dexterity Test (MDT) and predictors...
9.
Lorscheider J, Signori A, Subramaniam S, Benkert P, Vukusic S, Trojano M, et al.
J Neurol Neurosurg Psychiatry
. 2024 Dec;
PMID: 39643429
Background: Effectiveness of disease-modifying treatment (DMT) in people affected by primary progressive multiple sclerosis (PPMS) is limited. Whether specific subgroups may benefit more from DMT in a real-world setting remains...
10.
Siriratnam P, Huda S, van der Walt A, Sanfilippo P, Sharmin S, Foong Y, et al.
Neurology
. 2024 Nov;
103(12):e209940.
PMID: 39561307
Objectives: In aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (AQP4-IgG NMOSD), disability accrual is mostly attributed to relapses. This study aimed to assess the prevalence of progression independent of relapse activity...